Eli Lilly today entered into an agreement for $2.8 billion to acquire AtaiBeckley. The main reason for this big pharma doing so is so that it could get its hands on the company’s development of its synthetic form of 5-MeO-DMT, BPL-003 [mebufotenin benzoate], which is being developed for treatment-resistant depression [TRD].

AtaiBeckley was gearing up to initiate its pivotal phase 3 ReConnection study program to advance BPL-003 for these TRD patients in Q2 of 2026. It appears that Eli Lilly has decided to make a move to acquire it before it was able to initiate such a late-stage study program.

Such an acquisition didn’t just happen randomly out of nowhere. There was a major reason for Eli Lilly wanting to get its hands on BPL-003, and it was likely based on phase 2b data. In a phase 2b study, it was shown that patients who received this therapy intranasally were able to achieve rapid and durable reductions in symptoms. What’s even more impressive is that it was able to achieve this when patients only needed to complete a 2-hour in-clinic visit. In addition to the fact that responses lasted several months afterwards.

Everyone gets some type of depression at some point, which can last several days. First and foremost, such patients experience major depressive disorder [MDD], which is characterized as depression that lasts at least 2 weeks or longer. With that said, TRD comes about when such patients remain symptomatic despite receiving two first-line antidepressant therapies.

Just how well did this BPL-003 therapy work for these TRD patients? Consider that over a 29-day evaluation period, it was shown that a single 12 mg dose of this drug was able to reduce depressive symptoms in a statistically significant manner based on a scale known as the Montgomery-Åsberg Depression Rating Scale [MADRS], with a p-value of p=0.0038. The premise is that BPL-003 patients achieved an average decrease score of 11.1 points from baseline, while those on the 0.3 mg comparator group [low dose comparator therapy is used for psychedelic studies as opposed to placebo] only saw a 5.5-point reduction.

Beyond the scope of such a short period of time, it is important to see an effect that is durable and/or long-lasting. That’s exactly what was shown with this very same released data. Both the 8 mg and 12 mg doses of BPL-003 were able to maintain statistical significance in terms of MADRS all the way to 8 weeks. On top of a majority of patients seeing such an effect as early as the first day.

The terms of the buyout for $2.8 billion correspond to $6.75 per share in cash. The reason why this is important is because there is another $1 billion, or $2.50 per share in cash, that is being tied to a contingent value right [CVR]. What this means is that in order for shareholders to receive this CVR, there have to be specific development and regulatory milestones met with respect to BPL-003, along with VLS-01.

Speaking of VLS-01, I believe this is another reason why AtaiBeckley was likely acquired. It is because this other drug, which is oral buccal film DMT, is in the process of being evaluated in the phase 2b Elumina trial for TRD patients. Thus, the point here is that this offers another way that Eli Lilly could possibly capitalize on the TRD market. In other words, it acts as another shot on goal. Investors won’t have to wait long to see data from this mid-stage study using VLS-01 for TRD patients. That’s because topline results from the Elumina study are expected to be released in Q4 of 2026.

The truth is that VLS-01 might be the huge bonus for Eli Lilly. Why do I say that? It is because not only was there a plan to initiate a phase 3 study program using this other psychedelic drug to treat patients with major depressive disorder [MDD], but there was also a thought process of advancing it for the treatment of patients with generalized anxiety disorder [GAD] as well.

With receiving approval of AtaiBeckley stockholders and other customary closing conditions, this acquisition is expected to be completed in Q3 of 2026. The development pipeline for AtaiBeckley goes deeper. It even was in the process of developing an oral formulation of R-MDMA, EMP-01, for the treatment of patients with social anxiety disorder [SAD]. It released positive top-line results from a phase 2 study using this drug to treat these patients.

Although early, there were encouraging signals relating to secondary endpoints for EMP-01 treating these SAD patients. The hope is that something can happen with this program to help these patients. That’s because there have been no advancements in pharmacological treatments in over 20 years.